5 research outputs found
Laparoscopic Total Extraperitoneal (TEP) Inguinal Hernia Repair Using 3-dimensional Mesh Without Mesh Fixation
No full textLong-term outcome of radiocephalic dialysis access constructed with venous patch technique
No full textBurden of human papillomavirus infections and related diseases in the extended middle east and North Africa Region
No full textIn this chapter, we present the available information on the burden of human papillomavirus (HPV)-related cancers (cancers of the cervix, anogenital cancers, and cancers of the oral cavity and pharynx), as well as available data on the prevalence and distribution of HPV types in women with and without cervical cancer, for the countries of the Extended Middle East and North Africa region (EMENA). The EMENA region is characterized by societies that share similar cultures and religions and that are considered to have a more conservative sexual behaviour compared to Western societies. The incidence of cervical cancer is estimated to be relatively low, although it is difficult to assess precisely because systematic and national cancer registries are lacking in many countries of the EMENA region. In these countries, nationwide programs of cervical cancer screening do not exist or are based on a limited opportunistic cytology-based screening, which often lacks quality assurance. The incidence of anogenital cancers other than cervix is very low. The incidence of cancers of the oral cavity and pharynx is relatively high in some countries, particularly in Pakistan. Relatively low levels of HPV prevalence have been observed in the several surveys conducted in the EMENA region, although only few young women were included in these studies. Possible changes in lifestyle and sexual behaviour in younger generations might, however, change this scenario. Thus, improving the information on the burden of HPV-related cancers and on the HPV prevalence in the general population is essential to develop a comprehensive intervention policy for future management of cervical cancer in this area.This article forms part of a regional report entitled . Comprehensive Control of HPV Infections and Related Diseases in the Extended Middle East and North Africa Region Vaccine Volume 31, Supplement 6, 2013. Updates of the progress in the field are presented in a separate monograph entitled . Comprehensive Control of HPV Infections and Related Diseases Vaccine Volume 30, Supplement 5, 2012. © 2013 Elsevier Ltd.Aziz MTA, 2006, MED SCI MONITOR, V12, pMT43; Abd El-Azim S, 2011, CLIN LAB, V57, P363; Abdullah LS, 2007, ANN SAUDI MED, V27, P268; Ahmed MI, 2001, CLIN BIOCHEM, V34, P491, DOI 10.1016-S0009-9120(01)00243-0; Al-Awadhi R, 2011, J MED VIROL, V83, P453, DOI 10.1002-jmv.21981; Alhamany Z, 2010, J INFECT DEV COUNTR, V4, P732; Al Jaroudi D, 2010, ANN SAUDI MED, V30, P397, DOI [10.4103-0256-4947.68550, 10.4103-0236-4947.68330]; Allameh T, 2011, ARCH GYNECOL OBSTET, V284, P1509, DOI 10.1007-s00404-011-1863-4; Altun Z, 2011, TURK KLIN TIP BILIM, V31, P307, DOI 10.5336-medsci.2009-16463; Amrani M, 2003, J CLIN VIROL, V27, P286, DOI 10.1016-S1386-6532(02)00227-5; Balaha MH, 2011, J CYTOL, V28, P173, DOI 10.4103-0970-9371.86343; Bayram A, 2011, J MED VIROL, V83, P1997, DOI 10.1002-jmv.22218; Ben Aissa R, 2002, ONFP TUNIS MED, V80, P203; Bruni L, 2010, J INFECT DIS, V202, P1789, DOI 10.1086-657321; Chaouki N, 1998, INT J CANCER, V75, P546, DOI 10.1002-(SICI)1097-0215(19980209)75:4546::AID-IJC93.0.CO;2-T; Clifford GM, 2005, LANCET, V366, P991, DOI 10.1016-S0140-6736(05)67069-9; Curado MP, 2007, IARC SCI PUBLICATION, VIX; de Martel Catherine, 2012, Lancet Oncol, V13, P607, DOI 10.1016-S1470-2045(12)70137-7; de Sanjose S, 2010, LANCET ONCOL, V11, P1048, DOI 10.1016-S1470-2045(10)70230-8; De Vuyst H, 2009, INT J CANCER, V124, P1626, DOI 10.1002-ijc.24116; D'Souza G, 2007, NEW ENGL J MED, V356, P1944, DOI 10.1056-NEJMoa065497; Dursun P, 2009, BMC INFECT DIS, V9, DOI 10.1186-1471-2334-9-191; el-All Howayda S Abd, 2007, Infect Agent Cancer, V2, P12; El-Kak F, 2013, VACCINE, V31, pG45, DOI 10.1016-j.vaccine.2012.10.120; El Khair MM, 2010, MED ONCOL, V27, P861, DOI 10.1007-s12032-009-9297-6; Eren F, 2010, INT J GYNECOL OBSTET, V109, P235, DOI 10.1016-j.ijgo.2010.01.007; Esmaeili M, 2008, GYNECOL OBSTET INVES, V66, P68, DOI 10.1159-000134917; Ferlay J, 2010, IARC CANCERBASE; Franceschi S, 2005, BRIT J CANCER, V92, P601, DOI 10.1038-sj.bjc.6602348; Ghaffari Saeed Reza, 2006, Asian Pac J Cancer Prev, V7, P529; Ghazal-Aswad S, 2006, ACTA CYTOL, V50, P41, DOI 10.1159-000325893; Guan P, 2012, INT J CANCER, V131, P2349, DOI 10.1002-ijc.27485; Hajjaj AA, 2006, SAUDI MED J, V27, P487; Hamkar R, 2002, East Mediterr Health J, V8, P805; Hammouda D, 2005, INT J CANCER, V113, P483, DOI 10.1002-ijc.20600; Hammouda D, 2011, INT J CANCER, V128, P2224, DOI 10.1002-ijc.25539; Hassen E, 2003, INFECTION, V31, P143, DOI 10.1007-s15010-003-3112-7; Inal MM, 2007, INT J GYNECOL CANCER, V17, P1266, DOI 10.1111-j.1525-1438.2007.00944.x; Kapila K, 2006, MED PRIN PRACT, V15, P253, DOI 10.1159-000092986; Karabulut A, 2010, INT J GYNECOL OBSTET, V110, P40, DOI 10.1016-j.ijgo.2010.02.011; Karam WG, 2011, J BIOL REG HOMEOS AG, V25, P453; Karam WG, 2005, LEBAN MED J, V53, P132; Kasap B, 2011, EUR J OBSTET GYN R B, V159, P168, DOI 10.1016-j.ejogrb.2011.06.021; Keita N, 2009, BRIT J CANCER, V101, P202, DOI 10.1038-sj.bjc.6605140; Khan S, 2007, INT J INFECT DIS, V11, P313, DOI 10.1016-j.ijid.2006.06.007; Khodakarami N, 2012, INT J CANCER, V131, pE156, DOI 10.1002-ijc.26488; KrennHrubec K, 2011, J MED VIROL, V83, P651, DOI 10.1002-jmv.22011; Li N, 2011, INT J CANCER, V128, P927, DOI 10.1002-ijc.25396; Luthra UK, 2002, ACTA CYTOL, V46, P303, DOI 10.1159-000326726; Missaoui N, 2010, ASIAN PAC J CANCER P, V11, P235; Missaoui N, 2010, ANN BIOL CLIN-PARIS, V68, P297, DOI 10.1684-abc.2010.0431; Missaoui N, 2010, ASIAN PAC J CANCER P, V11, P777; Mortazavi S, 2002, ASIAN PAC J CANCER P, V3, P69; Mroueh AM, 2002, EUR J GYNAECOL ONCOL, V23, P429; MURRAY CJL, 1994, B WORLD HEALTH ORGAN, V72, P429; Nokiani FA, 2008, ASIAN PAC J CANCER P, V9, P107; Ozcan ES, 2011, J OBSTET GYNAECOL, V31, P656, DOI 10.3109-01443615.2011.597460; Ozgul N, 2008, J OBSTET GYNAECOL RE, V34, P865, DOI 10.1111-j.1447-0756.2008.00795.x; Ozturk Sual, 2004, Mikrobiyoloji Bulteni, V38, P223; Plummer M, 2012, INT J CANCER, V130, P2638, DOI 10.1002-ijc.26250; Rasul S, 1991, Asia Oceania J Obstet Gynaecol, V17, P1; Raza SA, 2010, BRIT J CANCER, V102, P1657, DOI 10.1038-sj.bjc.6605664; Safaei A, 2010, INDIAN J PATHOL MICR, V53, P681, DOI 10.4103-0377-4929.72030; Sancho-Garnier H, 2013, VACCINE, V31, pG51, DOI 10.1016-j.vaccine.2012.06.046; Seoud M, 2012, J LOW GENIT TRACT DI, V16, P106, DOI 10.1097-LGT.0b013e31823a0108; Shahsiah R, 2011, PATHOL RES PRACT, V207, P754, DOI 10.1016-j.prp.2011.09.011; Soerjomataram I, 2012, BMC MED RES METHODOL, V12, DOI 10.1186-1471-2288-12-125; Sughayer MA, 2010, INT J GYNECOL OBSTET, V108, P74, DOI 10.1016-j.ijgo.2009.08.025; Kara F, 2009, INT J GYNECOL OBSTET, V106, P206, DOI 10.1016-j.ijgo.2009.04.003; Usubutun A, 2009, INT J GYNECOL PATHOL, V28, P541, DOI 10.1097-PGP.0b013e3181aaba0d; Wasti S, 2004, ANN SAUDI MED, V24, P189; Yalti S, 2005, INT J GYNECOL CANCER, V15, P292, DOI 10.1111-j.1525-1438.2005.15218.x; YOUNIS N, 1993, STUD FAMILY PLANN, V24, P175, DOI 10.2307-2939232; Zandi K, 2010, VIROL J, V7, DOI 10.1186-1743-422X-7-65; Zavarei M, 2012, IRAN J PUBLIC HEALTH, V37, P10135
Surgeons’ practice and preferences for the anal fissure treatment: results from an international survey
No full textSurgeons’ practice and preferences for the anal fissure treatment: results from an international survey
No full text: The best nonoperative or operative anal fissure (AF) treatment is not yet established, and several options have been proposed. Aim is to report the surgeons' practice for the AF treatment. Thirty-four multiple-choice questions were developed. Seven questions were about to participants' demographics and, 27 questions about their clinical practice. Based on the specialty (general surgeon and colorectal surgeon), obtained data were divided and compared between two groups. Five-hundred surgeons were included (321 general and 179 colorectal surgeons). For both groups, duration of symptoms for at least 6 weeks is the most important factor for AF diagnosis (30.6%). Type of AF (acute vs chronic) is the most important factor which guide the therapeutic plan (44.4%). The first treatment of choice for acute AF is ointment application for both groups (59.6%). For the treatment of chronic AF, this data is confirmed by colorectal surgeons (57%), but not by the general surgeons who prefer the lateral internal sphincterotomy (LIS) (31.8%) (p = 0.0001). Botulin toxin injection is most performed by colorectal surgeons (58.7%) in comparison to general surgeons (20.9%) (p = 0.0001). Anal flap is mostly performed by colorectal surgeons (37.4%) in comparison to general surgeons (28.3%) (p = 0.0001). Fissurectomy alone is statistically significantly most performed by general surgeons in comparison to colorectal surgeons (57.9% and 43.6%, respectively) (p = 0.0020). This analysis provides useful information about the clinical practice for the management of a debated topic such as AF treatment. Shared guidelines and consensus especially focused on operative management are required to standardize the treatment and to improve postoperative results
